Cerus (CERS) Total Non-Current Liabilities (2010 - 2026)
Cerus (CERS) reported Total Non-Current Liabilities of $149.2 million for Q1 2026, up 1.84% on a YoY basis from $146.5 million in Q1 2025, and down 1.52% sequentially from $151.5 million in Q4 2025.
Cerus (CERS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Cerus (CERS) has 17 years of Total Non-Current Liabilities data on file, last reported at $149.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 1.84% year-over-year to $149.2 million; the trailing twelve-month figure through Mar 2026 stood at $149.2 million (up 1.84% YoY), and the FY2025 full-year result was $151.5 million, up 8.11% from the prior year.
- Total Non-Current Liabilities eased to $149.2 million in Q1 2026, from $151.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $154.0 million in Q3 2023 to a low of $131.5 million in Q3 2024.
- A 5-year average of $143.1 million and a median of $144.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities decreased 14.63% in 2024 and rose 15.92% in 2025, its largest moves.
- Tracing CERS's Total Non-Current Liabilities over 5 years: stood at $146.0 million in 2022, then fell by 3.4% to $141.1 million in 2023, then slipped by 0.66% to $140.1 million in 2024, then grew by 8.11% to $151.5 million in 2025, then slipped by 1.52% to $149.2 million in 2026.
- Business Quant data shows CERS's Total Non-Current Liabilities at $149.2 million in Q1 2026, $151.5 million in Q4 2025, and $147.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.58 Bn | 176.28 Bn | 6.27 Bn | - |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 68.67 Bn | 67.22 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.66 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 28.34 Bn | 27.23 Bn | 750.30 Mn | 3.53 Bn |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.79 Bn | 1.98 Bn | 24.21 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | 3.57 Bn |
| 9 | Koninklijke Philips | 24.12 Bn | 21.00 Bn | 2.07 Bn | 9.85 Bn |
| 10 | Cerus | 600.87 Mn | 520.44 Mn | 27.89 Mn | 149.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.20 Mn |
| Dec 31, 2025 | 151.50 Mn |
| Sep 30, 2025 | 147.76 Mn |
| Jun 30, 2025 | 152.53 Mn |
| Mar 31, 2025 | 146.51 Mn |
| Dec 31, 2024 | 140.13 Mn |
| Sep 30, 2024 | 131.46 Mn |
| Jun 30, 2024 | 131.58 Mn |
| Mar 31, 2024 | 135.54 Mn |
| Dec 31, 2023 | 141.07 Mn |
| Sep 30, 2023 | 153.99 Mn |
| Jun 30, 2023 | 144.37 Mn |
| Mar 31, 2023 | 147.36 Mn |
| Dec 31, 2022 | 146.03 Mn |
| Sep 30, 2022 | 138.08 Mn |
| Jun 30, 2022 | 136.57 Mn |
| Mar 31, 2022 | 138.22 Mn |
| Dec 31, 2021 | 149.54 Mn |
| Sep 30, 2021 | 135.47 Mn |
| Jun 30, 2021 | 136.82 Mn |